Go Pro
→ This Junior Silver Explorer Is Closing In on Its Biggest Catalyst (From Wall Street Logic) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shs5 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+11.3%		$0.02
$0.00
▼
$0.23
N/AN/A63,700 shs18,021 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
$11.41
-0.6%		$8.49
$0.16
▼
$11.67
N/AN/A118,772 shs7,888 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%+15.46%-39.96%-88.71%
Apollomics, Inc. stock logo
APLMW
Apollomics
+11.35%-2.48%+13.77%-5.99%-28.96%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
-1.82%+13.84%+21.87%+107.40%+5,085.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.20
$0.12
▼
$3.00
N/AN/A5,049 shs5 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+11.3%		$0.02
$0.00
▼
$0.23
N/AN/A63,700 shs18,021 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
$11.41
-0.6%		$8.49
$0.16
▼
$11.67
N/AN/A118,772 shs7,888 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%+15.46%-39.96%-88.71%
Apollomics, Inc. stock logo
APLMW
Apollomics
+11.35%-2.48%+13.77%-5.99%-28.96%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
-1.82%+13.84%+21.87%+107.40%+5,085.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest RVMDW, ALVOW, APLMW, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
Revolution Medicines, Inc. stock logo
RVMDW
Revolution Medicines
378N/AN/AN/A

Recent News About These Companies

BeOne Medicines, Revolution Medicines Announce Clinical Collaboration, Asia Rights Deal
August 10 at 8:18 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/beone-medicines-revolution-medicines-announce-105345810.html
RBC Capital Sticks to Its Buy Rating for Revolution Medicines (RVMD)
August 9 at 7:49 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/3715814/rbc-capital-sticks-to-its-buy-rating-for-revolution-medicines-rvmd/
Wells Fargo Gives a Buy Rating to Revolution Medicines (RVMD)
August 9 at 7:49 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/3716145/wells-fargo-gives-a-buy-rating-to-revolution-medicines-rvmd/
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Medtronic (MDT)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDT/pressreleases/3714136/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-medtronic-mdt/
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-revolution-medicines-rvmd-become-131956736.html
Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks
July 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/revolution-medicines-rvmd-stock-looks-180930946.html
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)
July 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ALNY-Q/pressreleases/3237962/analysts-offer-insights-on-healthcare-companies-simulations-plus-slp-alnylam-pharma-alny-and-revolution-medicines-rvmd/
Revolution Medicines reports encouraging early data for zoldonrasib combinations in RAS G12D pancreatic cancer
July 3, 2026  |  thepharmaletter.comT
Revolution Medicines (RVMD) Reports Positive Zoldonrasib Trial Data Ahead Of Phase 3
July 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-reports-positive-043009266.html
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What's Next
July 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-revolution-medicines-rvmd-6-081505737.html
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA) and Revolution Medicines (RVMD)
June 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TEVA/pressreleases/2600019/analysts-offer-insights-on-healthcare-companies-teva-pharmaceutical-teva-and-revolution-medicines-rvmd/
Bernstein Remains a Hold on Revolution Medicines (RVMD)
June 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/2374606/bernstein-remains-a-hold-on-revolution-medicines-rvmd/
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
June 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pancreatic-cancer-drug-milestone-affirms-193008823.html
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?
June 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/revolution-medicines-rvmd-best-biotech-142351551.html
Bernstein Reaffirms Their Hold Rating on Revolution Medicines (RVMD)
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/2282042/bernstein-reaffirms-their-hold-rating-on-revolution-medicines-rvmd/
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Veeva Systems (VEEV)
June 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/2257715/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-veeva-systems-veev/
Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around Valuation
June 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4911059-revolution-medicines-more-landmark-data-doesnt-dispel-doubts-around-valuation
RVMD Stock Jumps Overnight: New Drug Heads To FDA After ‘Unprecedented’ 1-Year Survival Win In Pancreatic Cancer
June 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/rvmd-stock-jumps-overnight-drug-010104847.html?fr=sycsrp_catchall
Doctors stood up and cheered mid-presentation for this historic pancreatic cancer treatment
June 1, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/why-doctors-stood-up-and-cheered-mid-presentation-for-a-historic-pancreatic-cancer-treatment/ar-AA24xMBC
Revolution Medicines' pancreatic cancer pill doubles survival, cuts death risk 60% in trial as stock sits near all-time highs
June 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/revolution-medicines-pancreatic-cancer-pill-doubles-survival-cuts-death-risk-60-in-trial-as-stock-sits-near-all-time-highs/ar-AA24wB7g

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 08/10/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.02 +0.00 (+11.35%)
As of 08/11/2026 03:40 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 08/10/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMDW

$11.41 -0.07 (-0.64%)
Closing price 08/11/2026 03:59 PM Eastern
Extended Trading
$11.45 +0.04 (+0.37%)
As of 08/11/2026 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas